Proteon Therapeutics, Inc. (NASDAQ:PRTO) Files An 8-K Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition.

On May 10, 2017, the Company issued a press release announcing
its financial results for the first quarter ended March 31, 2017.
A copy of such press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference in its entirety.

Item 7.01. Regulation FD Disclosure.

On May 10, 2017, the Company issued a press release announcing
that its investigational treatment, vonapanitase, has received
Breakthrough Therapy designation from the U.S. Food and Drug
Administration. The press release is attached to this Current
Report as Exhibit 99.2 hereto and is incorporated herein by
reference.

The information in this Current Report on Form 8-K under Items
2.02 and 7.01, including the exhibits attached hereto, shall not
be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that Section, and
shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

About Proteon Therapeutics, Inc. (NASDAQ:PRTO)

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Recent Trading Information

Proteon Therapeutics, Inc. (NASDAQ:PRTO) closed its last trading session up +0.05 at 1.35 with 42,859 shares trading hands.